First human test of experimental clotting drug begins
NCT ID NCT06669234
Summary
This is the first human study of an experimental drug called ALN-F1202, which targets a protein involved in blood clotting. The main goal is to check if the drug is safe and well-tolerated in 56 healthy volunteers. Researchers will give different single doses to see how the body handles the drug and what effects it has on basic blood clotting tests.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Clinical Pharmacology University Hospitals Leuven (UZ Leuven)
Leuven, Vlaams-Brabant, 3000, Belgium
Conditions
Explore the condition pages connected to this study.